Updating results

480 results

Sort: Relevance | Date

Care and support of people growing older with learning disabilities (NG96)

This guideline covers care and support for adults with learning disabilities as they grow older. It covers identifying changing needs, planning for the future, and delivering services including health, social care and housing. It aims to support people to access the services they need as they get older.

NICE guideline Published April 2018

Learning disabilities and behaviour that challenges: service design and delivery (NG93)

This guideline covers services for children, young people and adults with a learning disability (or autism and a learning disability) and behaviour that challenges. It aims to promote a lifelong approach to supporting people and their families and carers, focusing on prevention and early intervention and minimising inpatient admissions.

NICE guideline Published March 2018

Managing medicines in care homes (SC1)

This guideline covers good practice for managing medicines in care homes. It aims to promote the safe and effective use of medicines in care homes by advising on processes for prescribing, handling and administering medicines. It also recommends how care and services relating to medicines should be provided to people living in care homes.

Social care guideline Published March 2014

Child abuse and neglect (NG76)

This guideline covers recognising and responding to abuse and neglect in children and young people aged under 18. It covers physical, sexual and emotional abuse, and neglect. The guideline aims to help anyone whose work brings them into contact with children and young people to spot signs of abuse and neglect and to know how to respond. It also supports practitioners who carry out assessments and provide early help and interventions to children, young people, parents and carers.

NICE guideline Published October 2017

Intermediate care including reablement (NG74)

This guideline covers referral and assessment for intermediate care and how to deliver the service. Intermediate care is a multidisciplinary service that helps people to be as independent as possible. It provides support and rehabilitation to people at risk of hospital admission or who have been in hospital. It aims to ensure people transfer from hospital to the community in a timely way and to prevent unnecessary admissions to hospitals and residential care.

NICE guideline Published September 2017

People's experience in adult social care services: improving the experience of care and support for people using adult social care services (NG86)

This guideline covers the care and support of adults receiving social care in their own homes, residential care and community settings. It aims to help people understand what care they can expect and to improve their experience by supporting them to make decisions about their care.

NICE guideline Published February 2018

Transition between inpatient hospital settings and community or care home settings for adults with social care needs (NG27)

This guideline covers the transition between inpatient hospital settings and community or care homes for adults with social care needs. It aims to improve people's experience of admission to, and discharge from, hospital by better coordination of health and social care services.

NICE guideline Published December 2015

Older people with social care needs and multiple long-term conditions (NG22)

This guideline covers planning and delivering social care and support for older people who have multiple long-term conditions. It promotes an integrated and person-centred approach to delivering effective health and social care services.

NICE guideline Published November 2015

Home care: delivering personal care and practical support to older people living in their own homes (NG21)

This guideline covers the planning and delivery of person-centred care for older people living in their own homes (known as home care or domiciliary care). It aims to promote older people's independence and to ensure safe and consistently high quality home care services.

NICE guideline Published September 2015

Managing medicines for adults receiving social care in the community (NG67)

This guideline covers medicines support for adults (aged 18 and over) who are receiving social care in the community. It aims to ensure that people who receive social care are supported to take and look after their medicines effectively and safely at home. It gives advice on assessing if people need help with managing their medicines, who should provide medicines support and how health and social care staff should work together.

NICE guideline Published March 2017

Transition between inpatient mental health settings and community or care home settings (NG53)

This guideline covers the period before, during and after a person is admitted to, and discharged from, a mental health hospital. It aims to help people who use mental health services, and their families and carers, to have a better experience of transition by improving the way it’s planned and carried out.

NICE guideline Published August 2016

Transition from children's to adults' services for young people using health or social care services (NG43)

This guideline covers the period before, during and after a young person moves from children's to adults' services. It aims to help young people and their carers have a better experience of transition by improving the way it’s planned and carried out. It covers both health and social care.

NICE guideline Published February 2016

Decision-making and mental capacity (NG108)

This guideline covers decision-making in people 16 years and over who may lack capacity now or in the future. It aims to help health and social care practitioners support people to make their own decisions where they have the capacity to do so. It also helps practitioners to keep people who lack capacity at the centre of the decision-making process.

NICE guideline Published October 2018

Supporting adult carers (NG150)

This guideline covers support for adults (aged 18 and over) who provide unpaid care for anyone aged 16 or over with health or social care needs. It aims to improve the lives of carers by helping health and social care practitioners identify people who are caring for someone and give them the right information and support. It covers carers’ assessments, practical, emotional and social support and training, and support for carers providing end of life care.

NICE guideline Published January 2020

Botulinum toxin type A for the prevention of headaches in adults with chronic migraine (TA260)

Evidence-based recommendations on botulinum toxin type A (Botox) for the prevention of headaches in adults with chronic migraine

Technology appraisal guidance Published June 2012

Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen (TA259)

Evidence-based recommendations on abiraterone (Zytiga) for castration-resistant metastatic prostate cancer in adults previously treated with docetaxel

Technology appraisal guidance Published June 2012 Last updated July 2016

Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer (TA258)

Evidence-based recommendations on erlotinib (Tarceva) for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer

Technology appraisal guidance Published June 2012

Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2 (TA257)

Evidence-based recommendations on lapatinib (Tyverb) or trastuzumab (Herceptin) combined with an aromatase inhibitor for the first-line treatment of..

Technology appraisal guidance Published June 2012

Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation (TA256)

Evidence-based recommendations on rivaroxaban (Xarelto) for preventing stroke and systemic embolism in atrial fibrillation (AF)

Technology appraisal guidance Published May 2012

Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosis (TA254)

Evidence-based recommendations on fingolimod (Gilenya) for treating highly active relapsing–remitting multiple sclerosis (MS)

Technology appraisal guidance Published April 2012

Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation (TA249)

Evidence-based recommendations on dabigatran etexilate (Pradaxa) for preventing stroke and systemic embolism in atrial fibrillation (AF)

Technology appraisal guidance Published March 2012

Tocilizumab for the treatment of rheumatoid arthritis (TA247)

Evidence-based recommendations on tocilizumab (RoActemra) for treating rheumatoid arthritis

Technology appraisal guidance Published February 2012

Pharmalgen for the treatment of bee and wasp venom allergy (TA246)

Evidence-based recommendations on Pharmalgen (ALK-Abelló) for treating bee and wasp venom allergy

Technology appraisal guidance Published February 2012

Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults (TA245)

Evidence-based recommendations on apixaban (Eliquis) for preventing venous thromboembolism (VTE) after total hip or knee replacement in adults

Technology appraisal guidance Published January 2012

Rituximab for the first-line treatment of stage III-IV follicular lymphoma (TA243)

Evidence-based recommendations on rituximab (MabThera) for the first-line treatment of stage III–IV follicular lymphoma

Technology appraisal guidance Published January 2012

Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy: Cetuximab (monotherapy or combination chemotherapy), bevacizumab (in combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (TA242)

Evidence-based recommendations on cetuximab (Erbitux), bevacizumab (Avastin) and panitumumab (Vectibix) for treating metastatic colorectal cancer..

Technology appraisal guidance Published January 2012

Panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer (terminated appraisal) (TA240)

NICE is unable to recommend the use in the NHS of panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer..

Technology appraisal guidance Published December 2011 Last updated March 2017

Fulvestrant for the treatment of locally advanced or metastatic breast cancer (TA239)

Evidence-based recommendations on fulvestrant (Faslodex) for treating locally advanced or metastatic breast cancer

Technology appraisal guidance Published December 2011

Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema in phakic eyes after an inadequate response to previous therapy (TA613)

Evidence-based recommendations on fluocinolone acetonide intravitreal implant (Iluvien) for chronic diabetic macular oedema that has inadequately responded to

Technology appraisal guidance Published November 2019

Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (TA611)

Evidence-based recommendations on rucaparib (Rubraca) for relapsed platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer that has responded to

Technology appraisal guidance Published November 2019

Pentosan polysulfate sodium for treating bladder pain syndrome (TA610)

Evidence-based recommendations on pentosan polysulfate sodium (Elmiron) for bladder pain syndrome in adults

Technology appraisal guidance Published November 2019

Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C (TA75)

Evidence-based recommendations on interferon alfa (pegylated and non-pegylated) and ribavirin for treating chronic hepatitis C

Technology appraisal guidance Published January 2004 Last updated November 2013

Pre-hospital initiation of fluid replacement therapy in trauma (TA74)

Evidence-based recommendations on giving intravenous (IV) fluid replacement therapy for people with serious injuries before reaching hospital

Technology appraisal guidance Published January 2004

Myocardial perfusion scintigraphy for the diagnosis and management of angina and myocardial infarction (TA73)

Evidence-based recommendations on myocardial perfusion scintigraphy (MPS) for diagnosing and managing angina and myocardial infarction (MI)

Technology appraisal guidance Published November 2003 Last updated July 2011

Guidance on the use of coronary artery stents (TA71)

Evidence-based recommendations on coronary artery stents for treating coronary artery disease (CAD)

Technology appraisal guidance Published October 2003 Last updated July 2008

Guidance on the use of imatinib for chronic myeloid leukaemia (TA70)

Evidence-based recommendations on imatinib (Glivec) for treating chronic myeloid leukaemia (CML)

Technology appraisal guidance Published October 2003 Last updated January 2016

Guidance on the use of liquid-based cytology for cervical screening (TA69)

Evidence-based recommendations on liquid-based cytology (LBC) for cervical screening

Technology appraisal guidance Published October 2003

Human growth hormone (somatropin) in adults with growth hormone deficiency (TA64)

Evidence-based recommendations on human growth hormone (somatropin; Genotropin, Humantrope, Norditropin, Saizen) in adults with growth hormone deficiency

Technology appraisal guidance Published August 2003

HealOzone for the treatment of tooth decay (occlusal pit and fissure caries and root caries) (TA92)

Evidence-based recommendations on HealOzone (ozone-releasing device) for treating tooth decay (occlusal pit/fissure caries/root caries)

Technology appraisal guidance Published July 2005

Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours (TA86)

Evidence-based recommendations on imatinib for treating unresectable and/or metastatic gastrointestinal stromal tumours (GIST/soft tissue sarcoma)

Technology appraisal guidance Published October 2004 Last updated November 2010

Laparoscopic surgery for inguinal hernia repair (TA83)

Evidence-based recommendations on laparoscopic (keyhole) surgery for repairing inguinal hernia (hernia in groin)

Technology appraisal guidance Published September 2004

Tacrolimus and pimecrolimus for atopic eczema (TA82)

Evidence-based recommendations on non-steroidal tacrolimus and pimecrolimus for treating atopic eczema (atopic dermatitis)

Technology appraisal guidance Published August 2004

Frequency of application of topical corticosteroids for atopic eczema (TA81)

Evidence-based recommendations on the frequency of application of topical corticosteroids for treating atopic eczema (atopic dermatitis)

Technology appraisal guidance Published August 2004

Fluid-filled thermal balloon and microwave endometrial ablation techniques for heavy menstrual bleeding (TA78)

Evidence-based recommendations on fluid-filled thermal balloon and microwave endometrial ablation techniques for treating heavy menstrual bleeding (HMB)

Technology appraisal guidance Published April 2004

Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia (TA77)

Evidence-based recommendations using zolpidem and zopiclone (the Z-drugs) for the short-term management of insomnia (sleeplessness) in adults

Technology appraisal guidance Published April 2004

Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer (TA61)

Evidence-based recommendations on capecitabine for treating metastatic colorectal cancer in adults

Technology appraisal guidance Published May 2003

Ramucirumab for treating unresectable hepatocellular carcinoma after sorafenib (terminated appraisal) (TA609)

NICE is unable to make a recommendation about the use in the NHS of ramucirumab (Cyramza) for treating unresectable hepatocellular carcinoma after sorafenib

Technology appraisal guidance Published October 2019

Ibrutinib with rituximab for treating Waldenstrom's macroglobulinaemia (terminated appraisal) (TA608)

NICE is unable to make a recommendation about the use in the NHS of ibrutinib (Imbruvica) with rituximab for treating Waldenstrom’s macroglobulinaemia in adults

Technology appraisal guidance Published October 2019

Lanadelumab for preventing recurrent attacks of hereditary angioedema (TA606)

Evidence-based recommendations on lanadelumab (Takhzyro) for preventing recurrent attacks of hereditary angioedema in people aged 12 and over

Technology appraisal guidance Published October 2019

Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (TA605)

Evidence-based recommendations on Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (excessive salivation and drooling) in adults

Technology appraisal guidance Published October 2019